ROS Therapeutics ApS: Financial statements 2020
CVR: 39507501
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -2,037,635 and a net result of DKK -1,900,359 compared with DKK -1,883,000 the year before. Equity in the 2020 report amounted to DKK 3,623,456. The solvency ratio was 35.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -2,037,635
- Profit/Loss
- DKK -1,900,359
- Equity
- DKK 3,623,456
- Total Assets
- DKK 10,176,318
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -2 mio. | -1.9 mio. | 3.6 mio. | 1 |
| 2019 | - | -2.1 mio. | -1.9 mio. | 5 mio. | 0 |
Official annual report
How creditworthy is ROS Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of October 2, 2020, Morten Amstrup Sandlykke has joined the board of directors of ROS Therapeutics ApS.
As of September 7, 2020, Sandlykke A/S is registered as an owner of ROS Therapeutics ApS with an ownership share of 10%.
As of September 7, 2020, HDJ & LEJ Invest ApS is registered as an owner of ROS Therapeutics ApS with an ownership share of 5%.
As of September 7, 2020, ROS Therapeutics Holding ApS is registered as an owner of ROS Therapeutics ApS with an ownership share of 50%.
As of June 29, 2020, A/S PSE 17 NR. 1056 has been appointed auditor of ROS Therapeutics ApS.
As of June 29, 2020, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of ROS Therapeutics ApS.
ROS Therapeutics ApS has published its annual report for 2019. Gross profit came to DKK -2,140,000, and the net result was DKK -1,883,000.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.